New Combination Treatment Boosts Immunotherapy Success Against Glioblastoma Brain Cancer
Combining a drug that restores oxygen in tumours with an immune booster helped mice fight glioblastoma and build lasting protection.

Scientists at The Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. In a new study published in Neuro-Oncology in 2026, the researchers showed that reprogramming myeloid cells, a type of immune cell that glioblastoma tumours co-opt to protect themselves, while simultaneously boosting T cells that fight cancer shrank the tumours and prevented them from coming back.
“Immunotherapy works in many different cancer types, but the same approach has yielded a success rate of less than 10% in glioblastoma,” said Filippo Veglia, PhD, assistant professor in the Genome Regulation and Cell Signaling Program at The Wistar Institute and senior author of the study. “Our study shows that combination therapy is paramount to making immunotherapy work for glioblastoma patients. We need to target two different populations of cells.”
Glioblastoma is the most aggressive and deadly primary brain cancer in adults. Immunotherapies that have transformed care for other cancers have largely failed against it, in part because glioblastoma tumours are packed with myeloid cells. Inside the tumour, these cells suppress the immune system by shutting down nearby T cells that would otherwise attack the cancer. The few functional T cells that do reach the tumours face a second problem. They become chronically active, which wears them down into a dysfunctional state called exhaustion, leaving them unable to kill tumour cells.
Veglia’s lab first set out to uncover the mechanism that causes myeloid cells inside glioblastoma tumours to become immunosuppressive. By taking a cell-by-cell inventory of the immune cells inside tumours in a preclinical model, the researchers discovered that the two most abundant and immunosuppressive myeloid cell types in the tumour both showed strong signs of hypoxia, or oxygen starvation. In the lab, they confirmed that hypoxia was a critical factor in recruiting myeloid cells to shield the tumour, as low oxygen alone was enough to convert these cells into potent suppressors of T cells.
To relieve hypoxia in the tumour, the researchers used a low dose of axitinib, a drug already used in combination with immunotherapy to treat advanced kidney cancer. In the preclinical model, axitinib reduced oxygen starvation inside the tumour and stopped myeloid cells from being reprogrammed to suppress T cells. As a result, more T cells entered the tumour. However, axitinib alone extended median survival only modestly, from 17–19 days.
“By reducing hypoxia, we can impair the immunosuppressive activity of myeloid cells, and this results in the accumulation of more T cells in the tumour microenvironment. But this is not enough, because when T cells go into the tumour, they are not efficiently able to eradicate tumours,” said Veglia.
Many of the T cells that accumulated in the tumour after axitinib treatment were marked by the receptor 4-1BB, indicating that they had recognised the cancer target they wanted to attack. Notably, 4-1BB largely marked effector-like exhausted T cells: T cells that are on their way to exhaustion but have not yet reached a terminal, dysfunctional state. In other words, these T cells are getting worn down but still retain the ability to attack cancer. The team reasoned that activating 4-1BB using an immunotherapeutic approach could boost both the number and the quality of these T cells.
“The combination of axitinib and the 4-1BB agonist was far more powerful than either treatment alone,” said Veglia. The combined treatments extended median survival to 42 days in murine models, with a 40% long-term survival rate. Furthermore, re-exposure to tumour cells later did not incite new tumour growth, indicating that the immune system had developed lasting memory against the cancer. The findings show that addressing myeloid cell suppression and T cell exhaustion together can produce durable immunity against tumours in preclinical models.
Veglia hopes to test the combination in a clinical trial with glioblastoma patients. Because the approach builds on an existing approved drug and a targeted immune agonist, researchers note that it raises the prospect of future clinical evaluation for patients with limited current options. His lab also plans to experiment with pairing axitinib and CAR T-cell therapy to see whether relieving hypoxia can help engineered T cells become more effective against solid tumours, where they currently struggle. Because hypoxic tumours are among the most resistant to immunotherapy, Veglia believes the strategy could eventually extend beyond the brain to cancers such as pancreatic cancer, which is also highly hypoxic.
“There are no cures for glioblastoma, so this is an opportunity to make a real difference for patients,” Veglia said. “We are also excited to see if our findings extend to other types of recalcitrant cancer and ultimately improve outcomes for these patients, too.”